Key facts
- It has raised $55.6M; the latest was Later Stage VC ($17.2M) in Jul 2025.
- Notable investors include Mirae Asset Capital, Premier Partners, NH Investment & Securities, K& Investment Partners, Ulysses Capital — 20 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 20 names
- ·Watchlist + deal alerts for SoVarGen
- ·The full record, as it builds
Funding rounds
No funding rounds for SoVarGen are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SoVarGen
Developer of novel therapeutics and diagnostics designed to treat intractable central nervous system (CNS) diseases caused by low-level somatic mutation. The company provides differentiated research and development methods and resources to overcome the limitations of existing brain disease treatment development and present a new paradigm for developing treatments, enabling patients to get effective therapies in less time.
- Sector
- Healthcare
- HQ
- Daejeon, South Korea
- Founded
- 2018
- Employees
- 31
- Website
- sovargen.com/
- Ownership
- Privately Held (backing)
SoVarGen doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SoVarGen shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SoVarGen in its N-PORT filings yet. We sweep new filings monthly.